MA-SIMPLIVITY
SimpliVity, a leader in hyperconverged infrastructure for IT , announced today it has raised $175 million in series D funding at a valuation of more than $1 billion – a record achievement just 23 months after general availability of OmniCube, its flagship product. Waypoint Capital, the business enterprise for the Bertarelli family’s investments and headquartered in Geneva, Switzerland, led the round. Prior investors Accel Partners, Charles River Ventures, DFJ Growth, Kleiner Perkins Caufield & Byers (KPCB) and Meritech Capital Partners also contributed to the round. SimpliVity’s total venture funding is now $276 million.
Waypoint was inspired to make the investment after transforming its own IT environments across five global sites with SimpliVity’s hyperconverged infrastructure solution.
“As a customer, we experienced first-hand the transformational impact of SimpliVity’s hyperconverged infrastructure. After a thorough analysis of alternatives, we were convinced SimpliVity is technologically superior, and that its unique data architecture is years ahead of the market,” said Frederic Wohlwend, Chief Information and Technology Officer at Waypoint Capital. “When we learned SimpliVity was raising capital, we insisted on taking the lead. We see enormous potential in a company revolutionizing IT, and growing faster than any infrastructure company in recent history.”
“We are honored to have Waypoint join our extremely supportive group of investors. It is a unique and valuable opportunity to have an investor who is truly a customer first – with hands-on SimpliVity product experience,” said Doron Kempel, SimpliVity CEO. “The continued support from our existing investors is incredibly appreciated. Together, these investors give us the greatest strategic latitude for the business as we continue to optimize during this time of hyper growth.”
The financing will be used to fund the rapid expansion of the company and address the explosive market opportunity. Gartner predicts total integrated system spending will grow by a 24 percent CAGR from 2013 through 2018, reaching a total of $19 billion.
SimpliVity launched its hyperconverged infrastructure platform in April 2013 and delivered record growth in 2014. In 2014, SimpliVity grew revenues by more than 500 percent year over year; expanded with resellers into 50 countries and employees in 18; and grew its employee base to more than 400 worldwide. SimpliVity also partnered with Cisco in August 2014 in order to expand its global reach.
Morgan Stanley served as the sole placement agent for SimpliVity.
Supporting Quotes
“Legacy IT infrastructure is due for a shake-up and the market continues to show signs of acceleration,” said Mark Bowker, Senior Analyst, ESG. “There is significant interest in, and momentum behind hyperconverged infrastructure investments. Legacy architectures packaged and delivered with ‘a bow on top’ are failing to achieve the scale and operational efficiency we are seeing IT professionals achieve with a true hyperconverged platform like SimpliVity. This is the wave of the future and the path to modern IT infrastructure.”
“Accel Partners has not only invested in a company with a superior technology and enormous market opportunity, but in a leadership team that’s tuned to deliver,” said early investor and board member Kevin Comolli of Accel Partners. “This team has tremendous vision and one of the best abilities to execute that I’ve seen. SimpliVity has pioneered the hyperconverged infrastructure market and will emerge as a category leader. After just 23 months shipping product, the company has achieved an unprecedented sales trajectory.”
“When we first invested in SimpliVity, we saw a company that had the potential to transform how data is stored, managed and protected in the enterprise, which would truly impact one of the largest markets in technology,” said Bruce Sachs, General Partner, Charles River Ventures. “The growth of the customer base, product and management team has been very impressive and exceeded our expectations. SimpliVity has all of the right ingredients to lead in this market, and we are thrilled to be their business partners during this exciting time.”
“A $1+ billion valuation, and one of the largest rounds of venture capital ever for an enterprise company, are strong testaments to SimpliVity’s tremendous technology and massive addressable market,” said KPCB General Partner, Matt Murphy. “The product uptake and depth of penetration has been breathtaking: fully sixty-five percent of SimpliVity customers standardize all of their virtualized applications on SimpliVity’s platform.”
Additional Resources
- View the video and read the Waypoint case study
- Check out the microsite
- Learn more at SimpliVity’s blog
- Follow SimpliVity on Twitter , LinkedIn , Facebook , YouTube and Google+
About Waypoint
Waypoint Capital is a business enterprise for the managers and advisers of the funds and investments associated with the Bertarelli family. The group is active in two areas: life sciences and asset management, including real estate. Chaired by Ernesto Bertarelli, Waypoint is headquartered in Geneva, with offices in London, Jersey, Boston and Luxembourg. Visit www.waypointcapital.net for more information.
About SimpliVity
Founded with a mission to simplify IT, SimpliVity is a pioneer in the hyperconverged infrastructure market, disrupting the status quo of complex and cumbersome legacy IT systems. SimpliVity’s hyperconverged IT platform delivers enterprise-class performance and availability that today’s IT leaders require, with the cloud economics their business demands. No other company has taken on the mega task of assimilating all IT elements below the hypervisor (8-12 disparate functions) into a simple 2U building block of x86 sharable resources to deliver unmatched IT simplicity, operational efficiency, and 3x TCO savings. The company’s unique data virtualization architecture improves performance, protection and data efficiency, while also enabling global unified management from a single console. SimpliVity has revolutionized IT systems for hundreds of enterprises around the world. Headquartered in Westborough, Mass., the company has raised more than $276 million in venture capital and employs more than 400 worldwide. SimpliVity's business model is 100 percent indirect, and its solutions and professional services are available worldwide through its network of resellers and distributors. For more information, visit www.simplivity.com .
Note: SimpliVity, the SimpliVity logo, OmniCube, OmniStack, and Data Virtualization Platform are trademarks or registered trademarks of SimpliVity Corporation in the United States and certain other countries. All trademarks and registered trademarks mentioned herein belong to their respective owners.
Contact:
SimpliVity Media Contacts
North
America
SimpliVity
Melissa Mahoney, 508-720-8227
Vice
President, Communications
melissa.mahoney@simplivity.com
or
Version
2.0 Communications
Katelyn Holbrook, 617-426-2222
kholbrook@v2comms.com
or
EMEA
Axicom
Robin
Wolstenholme, +44 (0)208 3924079
robin.wolstenholme@axicom.com
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 07:00:00 CEST | Press release
- First patient enrolled in INFLAM MOTION, a global randomized Phase 2a trial including 129 knee osteoarthritis patients - 4P004 to be evaluated over 3 months for dual efficacy: symptom relief and synovial health improvement via contrast-enhanced MRI - Topline results expected in the second half of 2026 4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P
Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 19:06:00 CEST | Press release
With Qi2.2 certification, Belkin reinforces its commitment to quality, safety, and performance for the next generation of wireless charging Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The comp
Cessna Grand Caravan EX to Feature New Executive Interior Options, Expanding Opportunities for Elevated Missions15.7.2025 18:05:00 CEST | Press release
The legendary Cessna Grand Caravan EX will now feature three new executive interior schemes for customers to select when designing their aircraft cabin. The Lunar, Obsidian and Saddle Sport interiors join the existing Canyon and Savanna schemes, providing a broader range of standard choices. The new interior options are available to customers starting this month and allow them to further tailor the interior of their aircraft based on their personal preference or mission. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715021096/en/ Cessna Grand Caravan EX to feature new executive interior options, expanding opportunities for elevated missions (Photo Credit: Textron Aviation) The Cessna Grand Caravan EX is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company. Premium versions of each of the new interiors are also available, featuring quilted seat stitching and plush carpet, providing an elev
7 Million Tokens Sells Out in less than One Hour—$MBG Token Pre-Sale Shatters Expectations15.7.2025 17:27:00 CEST | Press release
MultiBank Group, the world’s largest and most regulated financial derivatives institution, has set a new benchmark in digital asset launches. The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715055611/en/ The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. Commenting on the success of the Pre-Sale, Naser Taher, Founder and Chairman of MultiBank Group, said: “The sell-out of our initial $MBG Token offering in less than one hour is a decisive validation of our vision. In a market saturated with speculation, the response we received confirms that institutional-grade transparency, regulatory integrity, and asset-backed value are what investors are now demanding. $MBG is here for the long term, reflecting t
First Patient Enrolled in National Cancer Institute’s Vanguard Study Evaluating Guardant Health’s Shield Multi-Cancer Detection Test15.7.2025 17:01:00 CEST | Press release
Study addressing feasibility of using multi-cancer detection tests in future trials aims to enroll up to 24,000 participantsShield MCD reviewed by FDA as part of NCI’s investigational device exemption (IDE) Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that patient enrollment has begun in the National Cancer Institute (NCI)’s Vanguard Study to evaluate emerging multi-cancer detection (MCD) technology. Guardant’s Shield™ MCD test was selected for use in the four-year study, which aims to enroll up to 24,000 patients and evaluate the use of MCD tests—blood tests that can screen for several types of cancer simultaneously—in future randomized controlled trials. Guardant’s Shield MCD test was chosen for the study based on the overall performance of its Shield platform in detecting 10 cancer types, including lung, breast, colorectal, prostate, bladder, ovarian, pancreatic, esophageal, liver and gastric. The data were presented at the 2025 American
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum